ArticleBlood2019
Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy.
Abstract readLetter
In one paragraph
Article in Blood, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Circulating plasma cells as a predictive biomarker in Multiple myeloma: an updated systematic review and meta-analysis.Annals of medicine · 2024Pooled it
- Trial
- Trial
- Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma.Leukemia · 2022Trial
- Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation.Blood cancer journal · 2021Trial
- Article
- Clinical implications of minimal residual disease monitoring in multiple myeloma.International journal of hematology · 2026Review
- Circulating tumour cells (CTCs) in haematological malignancies: Advances in biology and clinical relevance with a focus on multiple myeloma.British journal of haematology · 2026Review
- Review
- New Approaches for Measurable Residual Disease Assessment in Multiple Myeloma: Integrating NGS, Mass Spectrometry, and Next-Generation Flow Cytometry to Monitor Treatment Response.Current hematologic malignancy reports · 2026Review
- Guidelines and consensus for minimal residual disease-adapted therapy in multiple myeloma from the Pan-Pacific multiple myeloma working group.Clinical hematology international · 2026Article
- Minimal residual disease in multiple myeloma: the movement towards response-adapted therapy.Frontiers in immunology · 2026Review
- Clinical applications of mass spectrometry in multiple myeloma.Blood advances · 2025Review
- Article
- Characterizing circulating rare cells in peripheral blood for detecting and monitoring multiple myeloma and precursor states.NPJ precision oncology · 2025Article
- Impact of the kinetics of circulating anti-BCMA CAR-T cells and normal lymphocytes on the outcome of MM patients.HemaSphere · 2025Article
- Review
- SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors.Nature cancer · 2025Article
- Measurable residual disease in hematologic malignancies: a biomarker in search of a standard.EClinicalMedicine · 2025Review
- Minimal Residual Disease Significance in Multiple Myeloma Patients Treated with Anti-CD38 Monoclonal Antibodies.Pharmaceuticals (Basel, Switzerland) · 2025Review
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Luzalba Sanoja-FloresCancer Research Center-Instituto de Biología Celular y Molecular del Cáncer (IBMCC) of the Consejo Superior de Investigaciones Científicas (CSIC) and University of Salamanca (USAL), Salamanca, Spain.
Juan Flores-MonteroCancer Research Center-Instituto de Biología Celular y Molecular del Cáncer (IBMCC) of the Consejo Superior de Investigaciones Científicas (CSIC) and University of Salamanca (USAL), Salamanca, Spain.
Noemi PuigCancer Research Center-Instituto de Biología Celular y Molecular del Cáncer (IBMCC) of the Consejo Superior de Investigaciones Científicas (CSIC) and University of Salamanca (USAL), Salamanca, Spain.
Teresa Contreras-SanfelicianoDepartment of Biochemistry, University Hospital of Salamanca, Salamanca, Spain.
Roberia PontesDepartment of Pediatrics, Institute of Pediatrics and Puericulture Martagão Gesteira (IPPMG) and.
Alba Corral-MateosCancer Research Center-Instituto de Biología Celular y Molecular del Cáncer (IBMCC) of the Consejo Superior de Investigaciones Científicas (CSIC) and University of Salamanca (USAL), Salamanca, Spain.
Omar García-SánchezCancer Research Center-Instituto de Biología Celular y Molecular del Cáncer (IBMCC) of the Consejo Superior de Investigaciones Científicas (CSIC) and University of Salamanca (USAL), Salamanca, Spain.
María Díez-CampeloCancer Research Center-Instituto de Biología Celular y Molecular del Cáncer (IBMCC) of the Consejo Superior de Investigaciones Científicas (CSIC) and University of Salamanca (USAL), Salamanca, Spain.
Roberto José Pessoa de MagalhãesUniversity Hospital Clementino Fraga Filho, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil.
Luis García-MartínDepartment of Hematology, Hospital of Zamora, Zamora, Spain.
José María Alonso-AlonsoDepartment of Hematology, Hospital of Palencia, Palencia, Spain.
Aranzazú García-MateoDepartment of Hematology, Hospital of Segovia, Segovia, Spain.
Carlos Aguilar-FrancoDepartment of Hematology, Hospital of Soria, Soria, Spain.
Jorge LabradorDepartment of Hematology, Hospital of Burgos, Burgos, Spain.
Abelardo Barez-GarcíaDepartment of Hematology, Hospital of Ávila, Ávila, Spain.
Angelo MaiolinoUniversity Hospital Clementino Fraga Filho, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil.
Bruno PaivaCentro de Investigación Biomédica en Red de Cáncer (CIBER-ONC), Instituto Carlos III, Madrid, Spain.
Jesús San MiguelCentro de Investigación Biomédica en Red de Cáncer (CIBER-ONC), Instituto Carlos III, Madrid, Spain.
Elaine Sobral da CostaDepartment of Pediatrics, Institute of Pediatrics and Puericulture Martagão Gesteira (IPPMG) and.
Marcos GonzálezCancer Research Center-Instituto de Biología Celular y Molecular del Cáncer (IBMCC) of the Consejo Superior de Investigaciones Científicas (CSIC) and University of Salamanca (USAL), Salamanca, Spain.
María Victoria MateosCancer Research Center-Instituto de Biología Celular y Molecular del Cáncer (IBMCC) of the Consejo Superior de Investigaciones Científicas (CSIC) and University of Salamanca (USAL), Salamanca, Spain.
Brian DurieCedars-Sinai Samuel Oschin Cancer Center, Los Angeles, CA; and.
Jacques J M van DongenDepartment of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands.
Alberto OrfaoCancer Research Center-Instituto de Biología Celular y Molecular del Cáncer (IBMCC) of the Consejo Superior de Investigaciones Científicas (CSIC) and University of Salamanca (USAL), Salamanca, Spain.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Flow CytometryImmunophenotypingHumansMultiple MyelomaNeoplastic Cells, CirculatingPlasma CellsPrognosis
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.